title: Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: a case-matched cohort study in east China.
abstract: It is still controversial whether adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin can increase the overall survival of esophageal cancer patients, and which subgroup of patients get most benefits from it. Between 1998 and 2004, 66 esophageal cancer patients with adjuvant chemotherapy and 160 well-matched patients without chemotherapy were included in this study. Nine markers were measured in the protein level to analyze prognostic significance. In the whole group, adjuvant chemotherapy did not improve the survival of esophageal cancer patients. There was also no significant difference for survival in stage I (P=0.59 and P=0.59), stage II (P=0.28 and P=0.28) and stage III patients (P=0.144 and P=0.06) between the observation and the chemotherapy group. Chemotherapy was most effective for the patients who had metastases in cervical and/or celiac lymph nodes (IV subgroup). One and 3-year disease-free survival and overall survival were significantly better than for those who did not receive the chemotherapy(P=0.038, and 0.016, respectively). Bcl-2 expression was a bad prognostic factor, and was more predictive in the adjuvant chemotherapy group than in the no-chemotherapy group. Adjuvant chemotherapy significantly improved the treatment result of stage IV patients compared with the observation group. Bcl-2 could be used to analyze prognosis and guide the adjuvant treatment.
authors.affiliation: Department of Thoracic Surgery, Shanghai Cancer Hospital, Fudan University, Shanghai, China. zhang245@shca.org.cn
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: Y W
authors.initials: YW
authors.lastname: Zhang
authors.forename: Z W
authors.initials: ZW
authors.lastname: Chen
authors.forename: X Y
authors.initials: XY
authors.lastname: Zhou
authors.forename: S
authors.initials: S
authors.lastname: Lu
authors.forename: Q Q
authors.initials: QQ
authors.lastname: Luo
authors.forename: H
authors.initials: H
authors.lastname: Hu
authors.forename: L S
authors.initials: LS
authors.lastname: Miao
authors.forename: L F
authors.initials: LF
authors.lastname: Ma
authors.forename: J Q
authors.initials: JQ
authors.lastname: Xiang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002681:China; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil